Skip to content

Investigation of the effects of slow release carbohydrate digestion on satiety and related blood biomarkers of satiety and energy release

Investigation of the effects of slow release carbohydrate digestion on satiety and related blood biomarkers of satiety and energy release: A randomised, double blinded, crossover trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN46403895
Enrollment
38
Registered
2010-11-25
Start date
2010-06-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food metabolism Nutritional, Metabolic, Endocrine

Interventions

Each patient will undergo each of the following conditions on the same day of each week and with a minimum one week interval between study conditions: 1. Control (rapidly digestible starches) 2. 10g s

Sponsors

University of Ulster (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged between 19-55 years 2. Body Mass Index (BMI) > 20 and < 25 3. In good health condition (no cardiovascular, respiratory, neurological or metabolic disease such as diabetes) 4. Willing to consume the test products

Exclusion criteria

Exclusion criteria: 1. Regular use of medication (apart from OTC medication) 2. Smoking

Design outcomes

Primary

MeasureTime frame
Food and nutrient intake: 1. Energy intake (kJ) 2. Macronutrient intakes (g and % energy) 3. Weight of food and beverages (g) consumed Assessed following a test meal served 4 hours after consuming each of the test products.

Secondary

MeasureTime frame
1. Subjective satiety ratings: Visual analogue scales (VAS) to assess feelings of hunger, fullness, thirst, preoccupation with thoughts of food and desire to eat will be made on each study condition 2. Hormonal and metabolic responses: Blood samples will be taken at each study condition by venous cannula and analysed for the following metabolites: 2.1. Glucose 2.2. Insulin 2.3. Glucagon-Like Peptide (GLP-1) 2.4. Ghrelin 2.5. Peptide YY (PYY) (GLP-1, Ghrelin, and PYY only being analysed if there is a positive outcome for the outer measures)

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026